Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047

Natalia Ignatenko, Hagit F. Yerushalmi, Ritu Pandey, Karen L. Kachel, David E. Stringer, Laurence J. Marton, Eugene W. Gerner

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The conformationally restricted polyamine analog PG-11047 has significant growth inhibitory activity against prostate and lung cancer cell lines and is currently under evaluation in several clinical trials, both alone and in combination with other drugs, for the treatment of relapsed or refractory cancer. The objective of this study was to identify the molecular signature of genes responsive to PG-11047 treatment and the biochemical effects of this drug in the HCT116 colon cancer cell line. Materials and Methods: Gene expression analysis was performed using Affymetrix GeneChip human genome U133 Plus 2.0 arrays. Changes in protein expression were evaluated using 2D Polyacrylamide gels followed by LCMS/MS. Results: Treatment of cells with PG-11047 at concentrations ranging from 0.1 to 10 μM caused inhibition of cell growth. The activity of PG-11047 was found to correlate with its transcriptional effects on cell cycle control, focal adhesion, adherent and gap junction genes, MAPK-, Wnt- and, TGF-β signaling pathways, transport and DNA/RNA transcription factor genes. PG-11047 caused depletion of poly amine pools. Proteomics analysis showed that PG-11047 restricts the modification of eukaryotic translation initiation factor 5A (eIF5A), resulting in suppression of general protein synthesis in PG-11047-treated cells. Conclusion: These data show that PG-11047 has a broad spectrum of anticancer activity in colon cancer cells.

Original languageEnglish (US)
Pages (from-to)161-176
Number of pages16
JournalCancer Genomics and Proteomics
Volume6
Issue number3
StatePublished - May 2009

Fingerprint

Polyamines
Gene expression
Tumors
Colon
Gene Expression
Cells
Neoplasms
Genes
Colonic Neoplasms
RNA Transport
Cell Line
Wnt Signaling Pathway
Focal Adhesions
(N(1),N(12))bis(ethyl)-6,7-dehydrospermine
Gap Junctions
Cell growth
Human Genome
Growth
Cell Cycle Checkpoints
Pharmaceutical Preparations

Keywords

  • Affymetrix gene chip microarray
  • Colon cancer cells
  • PG-11047
  • Polyamine analogs
  • Polyamines

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Cancer Research
  • Biochemistry

Cite this

Ignatenko, N., Yerushalmi, H. F., Pandey, R., Kachel, K. L., Stringer, D. E., Marton, L. J., & Gerner, E. W. (2009). Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. Cancer Genomics and Proteomics, 6(3), 161-176.

Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. / Ignatenko, Natalia; Yerushalmi, Hagit F.; Pandey, Ritu; Kachel, Karen L.; Stringer, David E.; Marton, Laurence J.; Gerner, Eugene W.

In: Cancer Genomics and Proteomics, Vol. 6, No. 3, 05.2009, p. 161-176.

Research output: Contribution to journalArticle

Ignatenko, N, Yerushalmi, HF, Pandey, R, Kachel, KL, Stringer, DE, Marton, LJ & Gerner, EW 2009, 'Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047', Cancer Genomics and Proteomics, vol. 6, no. 3, pp. 161-176.
Ignatenko, Natalia ; Yerushalmi, Hagit F. ; Pandey, Ritu ; Kachel, Karen L. ; Stringer, David E. ; Marton, Laurence J. ; Gerner, Eugene W. / Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. In: Cancer Genomics and Proteomics. 2009 ; Vol. 6, No. 3. pp. 161-176.
@article{cf5b60b53bc04234aaafb7c95c057917,
title = "Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047",
abstract = "Background: The conformationally restricted polyamine analog PG-11047 has significant growth inhibitory activity against prostate and lung cancer cell lines and is currently under evaluation in several clinical trials, both alone and in combination with other drugs, for the treatment of relapsed or refractory cancer. The objective of this study was to identify the molecular signature of genes responsive to PG-11047 treatment and the biochemical effects of this drug in the HCT116 colon cancer cell line. Materials and Methods: Gene expression analysis was performed using Affymetrix GeneChip human genome U133 Plus 2.0 arrays. Changes in protein expression were evaluated using 2D Polyacrylamide gels followed by LCMS/MS. Results: Treatment of cells with PG-11047 at concentrations ranging from 0.1 to 10 μM caused inhibition of cell growth. The activity of PG-11047 was found to correlate with its transcriptional effects on cell cycle control, focal adhesion, adherent and gap junction genes, MAPK-, Wnt- and, TGF-β signaling pathways, transport and DNA/RNA transcription factor genes. PG-11047 caused depletion of poly amine pools. Proteomics analysis showed that PG-11047 restricts the modification of eukaryotic translation initiation factor 5A (eIF5A), resulting in suppression of general protein synthesis in PG-11047-treated cells. Conclusion: These data show that PG-11047 has a broad spectrum of anticancer activity in colon cancer cells.",
keywords = "Affymetrix gene chip microarray, Colon cancer cells, PG-11047, Polyamine analogs, Polyamines",
author = "Natalia Ignatenko and Yerushalmi, {Hagit F.} and Ritu Pandey and Kachel, {Karen L.} and Stringer, {David E.} and Marton, {Laurence J.} and Gerner, {Eugene W.}",
year = "2009",
month = "5",
language = "English (US)",
volume = "6",
pages = "161--176",
journal = "Cancer Genomics and Proteomics",
issn = "1109-6535",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047

AU - Ignatenko, Natalia

AU - Yerushalmi, Hagit F.

AU - Pandey, Ritu

AU - Kachel, Karen L.

AU - Stringer, David E.

AU - Marton, Laurence J.

AU - Gerner, Eugene W.

PY - 2009/5

Y1 - 2009/5

N2 - Background: The conformationally restricted polyamine analog PG-11047 has significant growth inhibitory activity against prostate and lung cancer cell lines and is currently under evaluation in several clinical trials, both alone and in combination with other drugs, for the treatment of relapsed or refractory cancer. The objective of this study was to identify the molecular signature of genes responsive to PG-11047 treatment and the biochemical effects of this drug in the HCT116 colon cancer cell line. Materials and Methods: Gene expression analysis was performed using Affymetrix GeneChip human genome U133 Plus 2.0 arrays. Changes in protein expression were evaluated using 2D Polyacrylamide gels followed by LCMS/MS. Results: Treatment of cells with PG-11047 at concentrations ranging from 0.1 to 10 μM caused inhibition of cell growth. The activity of PG-11047 was found to correlate with its transcriptional effects on cell cycle control, focal adhesion, adherent and gap junction genes, MAPK-, Wnt- and, TGF-β signaling pathways, transport and DNA/RNA transcription factor genes. PG-11047 caused depletion of poly amine pools. Proteomics analysis showed that PG-11047 restricts the modification of eukaryotic translation initiation factor 5A (eIF5A), resulting in suppression of general protein synthesis in PG-11047-treated cells. Conclusion: These data show that PG-11047 has a broad spectrum of anticancer activity in colon cancer cells.

AB - Background: The conformationally restricted polyamine analog PG-11047 has significant growth inhibitory activity against prostate and lung cancer cell lines and is currently under evaluation in several clinical trials, both alone and in combination with other drugs, for the treatment of relapsed or refractory cancer. The objective of this study was to identify the molecular signature of genes responsive to PG-11047 treatment and the biochemical effects of this drug in the HCT116 colon cancer cell line. Materials and Methods: Gene expression analysis was performed using Affymetrix GeneChip human genome U133 Plus 2.0 arrays. Changes in protein expression were evaluated using 2D Polyacrylamide gels followed by LCMS/MS. Results: Treatment of cells with PG-11047 at concentrations ranging from 0.1 to 10 μM caused inhibition of cell growth. The activity of PG-11047 was found to correlate with its transcriptional effects on cell cycle control, focal adhesion, adherent and gap junction genes, MAPK-, Wnt- and, TGF-β signaling pathways, transport and DNA/RNA transcription factor genes. PG-11047 caused depletion of poly amine pools. Proteomics analysis showed that PG-11047 restricts the modification of eukaryotic translation initiation factor 5A (eIF5A), resulting in suppression of general protein synthesis in PG-11047-treated cells. Conclusion: These data show that PG-11047 has a broad spectrum of anticancer activity in colon cancer cells.

KW - Affymetrix gene chip microarray

KW - Colon cancer cells

KW - PG-11047

KW - Polyamine analogs

KW - Polyamines

UR - http://www.scopus.com/inward/record.url?scp=67649464597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649464597&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 161

EP - 176

JO - Cancer Genomics and Proteomics

JF - Cancer Genomics and Proteomics

SN - 1109-6535

IS - 3

ER -